Article
Pharmacology & Pharmacy
Huijiang Liu, Ronghe Gu, Qian Huang, Yun Liu, Chong Liu, Shijie Liao, Wenyu Feng, Tianyu Xie, Jinmin Zhao, Jiake Xu, Qian Liu, Xinli Zhan
Summary: This study found that isoliensinine can inhibit the differentiation of osteoclasts and reduce bone loss, showing great potential for treating osteoporosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Nutrition & Dietetics
Ning Wang, Yongqiang Hao, Lingjie Fu
Summary: In osteoporosis, TMAO promotes osteoclast differentiation and bone loss by activating the ROS-dependent NF-kappa B signaling pathway.
Article
Plant Sciences
Honglin Chen, Gengyang Shen, Qi Shang, Peng Zhang, Die Yu, Xiang Yu, Zhida Zhang, Wenhua Zhao, Zixian Wu, Fuyu Tang, De Liang, Xiaobing Jiang, Hui Ren
Summary: The study demonstrates that Plastrum testudinis extract (PTE) can inhibit osteoclast differentiation and bone resorption in vitro, effectively alleviating bone loss caused by senile osteoporosis. Additionally, PTE can suppress osteoclast formation by blocking the NF-kappa B signaling pathway, presenting a potential therapeutic treatment for bone loss disorders.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
Zhihao Chen, Karthik Rajan Rajamanickam, Mina Ding, Sang Kyoon Kim, Sang-wook Park, Eunae Kim, Sunwoo Lee, Tae-Hoon Lee
Summary: In this study, we discovered a potent candidate, PMSA derivative 11, for suppressing mature osteoclasts formation in vitro through a TRAP staining assay. The bioactivity of PMSA derivatives was evaluated and 11 showed the most promising bioactivity, with an IC50 value of 322.9 nM, which was 15-fold better than PMSA-3-Ac. Mechanistically, 11 decreased the expression of genes required for osteoclastogenesis by blocking NFATc1 translocation. In vivo investigation demonstrated that 11 prevented excessive osteoclastogenesis-mediated bone loss in ovariectomized osteoporosis mimic mice. These findings highlight the therapeutic potential of 11 as a lead compound for anti-osteoporosis by targeting NFATc1 translocation.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Multidisciplinary Sciences
Yin Cheng, Haixia Liu, Jing Li, Yujie Ma, Changheng Song, Yuhan Wang, Pei Li, Yanjing Chen, Zhiguo Zhang
Summary: This study investigated the influence of different culture conditions on osteoclast differentiation in RAW264.7 cells. The results showed that RANKL treatment and cell density were important factors for osteoclast formation, while the addition of M-CSF had little effect. This research provides valuable insights into the optimal conditions for studying osteoclast function and mechanism.
Article
Endocrinology & Metabolism
Mengbo Zhu, Wenbin Xu, Jiuzhou Jiang, Yining Wang, Yanjing Guo, Ruijia Yang, Yaqiong Chang, Bin Zhao, Zhenyu Wang, Jianfeng Zhang, Te Wang, Liqin Shangguan, Shaowei Wang
Summary: The study found that peiminine can inhibit the differentiation and function of OCs by regulating the levels of specific genes and proteins, with potential targets including NF-kappa B and ERK1/2 signaling pathways. In an animal model, peiminine can alleviate bone loss in ovariectomized mice.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Zijiao Zhang, Juhan Song, Seung-Hee Kwon, Zhao Wang, Suk-Gyun Park, Xianyu Piao, Je-Hwang Ryu, Nacksung Kim, Ok-Su Kim, Sun-Hun Kim, Jeong-Tae Koh
Summary: This study found that pirfenidone (PFD) can significantly inhibit alveolar bone loss caused by ligature in mice. PFD may be a promising candidate for controlling periodontitis by suppressing osteoclastogenesis and inflammatory cytokine production through inhibiting the NF-kappa B signal pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Fumi Sato-Kaneko, Shiyin Yao, Fitzgerald S. Lao, Jason Nan, Jonathan Shpigelman, Annette Cheng, Tetsuya Saito, Karen Messer, Minya Pu, Nikunj M. Shukla, Howard B. Cottam, Michael Chan, Anthony J. Molina, Maripat Corr, Tomoko Hayashi, Dennis A. Carson
Summary: In this study, a novel adjuvant compound 2F52 was identified, which demonstrated potent immunomodulatory effects without the need for known pattern-recognition receptors. The compound showed promising results in enhancing immune responses and providing protective effects in a mouse model of lethal virus challenge. These findings suggest that compound 2F52 could be a valuable addition to vaccines as a safe and effective adjuvant.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biochemistry & Molecular Biology
Mina Ding, Eunjin Cho, Zhihao Chen, Sang-Wook Park, Tae-Hoon Lee
Summary: In this study, the effects of EPZ compounds, PRMT5 inhibitors, on RANKL-induced osteoclast differentiation were investigated. EPZ015866 attenuated osteoclast differentiation more effectively than EPZ015666. The compounds inhibited the nuclear translocation of NF-kappa B, preventing osteoclast differentiation and bone resorption. EPZ015866 may be a potential drug candidate for the treatment of osteoporosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Nutrition & Dietetics
Junquan Tian, Xuetai Bao, Fan Yang, Xiongzhuo Tang, Qian Jiang, Yuying Li, Kang Yao, Yulong Yin
Summary: Age-related osteoporosis is a common disease in the elderly, mainly caused by excessive activity of osteoclasts. Most approved drugs inhibit osteoclasts to treat osteoporosis. This study shows that supplementing dimethyl alpha-ketoglutarate (DM-AKG) can inhibit the differentiation of osteoclasts. The mechanism involves regulating NF-kappa B signaling pathway and oxidative phosphorylation through PHD1-dependent manner.
Article
Nutrition & Dietetics
Hye-Yeon Jang, Jeong-Mi Kim, Jong-Suk Kim, Byeong-Soo Kim, Young-Rae Lee, Jun Sang Bae
Summary: PBE inhibits osteoclast differentiation in BMMs by suppressing the RANKL-induced activated JNK/NF-κB/PLCγ2 signaling pathway and the expression of NFATc1 and c-Fos. PBE could be a potential therapeutic strategy or functional product for osteoclast-related bone disease.
Article
Food Science & Technology
Yan Zheng, Xing Wang, Ya-Jing Pan, Xiao-Feng Shi, Lei Yang, Yong-Liang Lou
Summary: In this study, it was found that Ori inhibits the production and activation of osteoclasts induced by RANKL, and reduces intracellular ROS levels by activating ROS-scavenging enzymes. It also downregulates the expression of c-Fos, NFATc1, CTSK, and NFATc2, which are genes and proteins unique to osteoclasts, by inhibiting RANKL-induced NF-κB. In the animal model, Ori therapy restores bone mass and improves microarchitecture.
FOOD SCIENCE & NUTRITION
(2023)
Article
Endocrinology & Metabolism
Chunchun Xue, Huan Luo, Libo Wang, Qing Deng, Wenyun Kui, Weiwei Da, Lin Chen, Shuang Liu, Yongpeng Xue, Jiafan Yang, Lingxing Li, Wenlan Du, Qi Shi, Xiaofeng Li
Summary: Aconine (AC) is a potential natural compound for treating osteoporosis by reversing osteoclast ferroptosis and formation mediated by NF-kappa B signaling.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xue Yang, Jiamin Liang, Ziyi Wang, Yuangang Su, Yunfei Zhan, Zuoxing Wu, Jing Li, Xuedong Li, Runfeng Chen, Jinmin Zhao, Jiake Xu, Qian Liu, Bo Zhou
Summary: This study found that sesamolin has the potential to treat osteoporosis by effectively inhibiting the formation of osteoclasts in vitro, attenuating bone loss through modulating multiple signaling pathways and gene expression, and demonstrating a preventive effect against bone loss induced by estrogen deficiency in vivo.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
Xuedong Li, Xixi Lin, Zuoxing Wu, Yuangang Su, Jiamin Liang, Runfeng Chen, Xue Yang, Lei Hou, Jinmin Zhao, Qian Liu, Feng Xu
Summary: The study demonstrates that PRI has therapeutic potential in treating osteolytic diseases like osteoporosis by inhibiting osteoclast formation and bone resorption activity both in vitro and in vivo. PRI exerts its effects through the suppression of NF-κB and ERK MAPK signaling pathways, preventing the production of mature osteoclasts.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)